AKL Therapeutics, is a privately held, pharmaceutical company, with an innovative approach to drug development including a new oral treatment for osteoarthritis

AKL Therapeutics develops synthetic medicines from small molecules found in plants, chosen for their record of activity and tolerability. These are made to pharmaceutical standards and taken through conventional clinical development.

Our lead asset is APPA, a fixed-dose oral combination of apocynin and paeonol for knee osteoarthritis (OA). APPA acts on several pathways that drive inflammation and joint damage in OA. It has completed three clinical trials, including a Phase 2b study, and has been generally well tolerated throughout.

OA affects more than 600 million people worldwide, and no approved medicine slows the disease. Current oral treatments relieve pain only, and their safety limits long-term use. APPA aims to be a well-tolerated oral option for patients with more severe disease, who have the highest unmet need.

AKL is led by a team with senior experience in inflammation drug development at Pfizer, Wyeth and Merck Serono, and works with leading OA clinicians and trial centers in the UK and Denmark. The company is based at [confirm: Stevenage Bioscience Catalyst, Hertfordshire], UK.

AKL is seeking a partner to take APPA forward. To discuss the opportunity, please contact us.